FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022161730> ?p ?o ?g. }

• W2022161730 endingPage "185" @default.
• W2022161730 startingPage "178" @default.
• W2022161730 abstract "In adults with non-promyelocytic acute myeloid leukemia (AML), high-dose cytarabine consolidation therapy has been shown to influence survival in selected patients, although the appropriate doses and schemes have not been defined. We evaluated survival after calculating the actual dose of cytarabine that patients received for consolidation therapy and divided them into 3 groups according to dose. We conducted a single-center, retrospective study involving 311 non-promyelocytic AML patients with a median age of 36 years (16-79 years) who received curative treatment between 1978 and 2007. The 131 patients who received cytarabine consolidation were assigned to study groups by their cytarabine dose protocol. Group 1 (n=69) received <1.5 g/m2 every 12 h on 3 alternate days for up to 4 cycles. The remaining patients received high-dose cytarabine (≥1.5 g/m2 every 12 h on 3 alternate days for up to 4 cycles). The actual dose received during the entire consolidation period in these patients was calculated, allowing us to divide these patients into 2 additional groups. Group 2 (n=27) received an intermediate-high-dose (<27 g/m2), and group 3 (n=35) received a very-high-dose (≥27 g/m2). Among the 311 patients receiving curative treatment, the 5-year survival rate was 20.2% (63 patients). The cytarabine consolidation dose was an independent determinant of survival in multivariate analysis; age, karyotype, induction protocol, French-American-British classification, and de novo leukemia were not. Comparisons showed that the risk of death was higher in the intermediate-high-dose group 2 (hazard ratio [HR]=4.51; 95% confidence interval [CI]: 1.81-11.21) and the low-dose group 1 (HR=4.43; 95% CI: 1.97-9.96) than in the very-high-dose group 3, with no significant difference between those two groups. Our findings indicated that very-high-dose cytarabine during consolidation in adults with non-promyelocytic AML may improve survival." @default.
• W2022161730 created "2016-06-24" @default.
• W2022161730 creator A5009290590 @default.
• W2022161730 creator A5019220020 @default.
• W2022161730 creator A5056473514 @default.
• W2022161730 creator A5071633044 @default.
• W2022161730 creator A5077322577 @default.
• W2022161730 date "2015-02-01" @default.
• W2022161730 modified "2023-09-26" @default.
• W2022161730 title "Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia" @default.
• W2022161730 cites W139603322 @default.
• W2022161730 cites W1492609361 @default.
• W2022161730 cites W1929561528 @default.
• W2022161730 cites W1970779268 @default.
• W2022161730 cites W1981640544 @default.
• W2022161730 cites W1990261520 @default.
• W2022161730 cites W1991253663 @default.
• W2022161730 cites W1996264890 @default.
• W2022161730 cites W2004477791 @default.
• W2022161730 cites W2010026460 @default.
• W2022161730 cites W2020413211 @default.
• W2022161730 cites W2047926103 @default.
• W2022161730 cites W2060191608 @default.
• W2022161730 cites W2069448515 @default.
• W2022161730 cites W2076426515 @default.
• W2022161730 cites W2079025304 @default.
• W2022161730 cites W2101301060 @default.
• W2022161730 cites W2113367077 @default.
• W2022161730 cites W2120440386 @default.
• W2022161730 cites W2131608086 @default.
• W2022161730 cites W2134458920 @default.
• W2022161730 cites W2144672860 @default.
• W2022161730 cites W2150113701 @default.
• W2022161730 cites W2151222524 @default.
• W2022161730 cites W2160746673 @default.
• W2022161730 cites W2164238912 @default.
• W2022161730 cites W2403556849 @default.
• W2022161730 cites W2414576850 @default.
• W2022161730 cites W273386428 @default.
• W2022161730 cites W4232020126 @default.
• W2022161730 cites W91972951 @default.
• W2022161730 doi "https://doi.org/10.1590/1414-431x20144059" @default.
• W2022161730 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4321225" @default.
• W2022161730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25517921" @default.
• W2022161730 hasPublicationYear "2015" @default.
• W2022161730 type Work @default.
• W2022161730 sameAs 2022161730 @default.
• W2022161730 citedByCount "2" @default.
• W2022161730 countsByYear W20221617302015 @default.
• W2022161730 countsByYear W20221617302020 @default.
• W2022161730 crossrefType "journal-article" @default.
• W2022161730 hasAuthorship W2022161730A5009290590 @default.
• W2022161730 hasAuthorship W2022161730A5019220020 @default.
• W2022161730 hasAuthorship W2022161730A5056473514 @default.
• W2022161730 hasAuthorship W2022161730A5071633044 @default.
• W2022161730 hasAuthorship W2022161730A5077322577 @default.
• W2022161730 hasBestOaLocation W20221617301 @default.
• W2022161730 hasConcept C104317684 @default.
• W2022161730 hasConcept C126322002 @default.
• W2022161730 hasConcept C141071460 @default.
• W2022161730 hasConcept C143998085 @default.
• W2022161730 hasConcept C185592680 @default.
• W2022161730 hasConcept C2776601000 @default.
• W2022161730 hasConcept C2778041864 @default.
• W2022161730 hasConcept C2778461978 @default.
• W2022161730 hasConcept C2778729363 @default.
• W2022161730 hasConcept C2779282312 @default.
• W2022161730 hasConcept C2781121885 @default.
• W2022161730 hasConcept C55493867 @default.
• W2022161730 hasConcept C71924100 @default.
• W2022161730 hasConcept C90924648 @default.
• W2022161730 hasConceptScore W2022161730C104317684 @default.
• W2022161730 hasConceptScore W2022161730C126322002 @default.
• W2022161730 hasConceptScore W2022161730C141071460 @default.
• W2022161730 hasConceptScore W2022161730C143998085 @default.
• W2022161730 hasConceptScore W2022161730C185592680 @default.
• W2022161730 hasConceptScore W2022161730C2776601000 @default.
• W2022161730 hasConceptScore W2022161730C2778041864 @default.
• W2022161730 hasConceptScore W2022161730C2778461978 @default.
• W2022161730 hasConceptScore W2022161730C2778729363 @default.
• W2022161730 hasConceptScore W2022161730C2779282312 @default.
• W2022161730 hasConceptScore W2022161730C2781121885 @default.
• W2022161730 hasConceptScore W2022161730C55493867 @default.
• W2022161730 hasConceptScore W2022161730C71924100 @default.
• W2022161730 hasConceptScore W2022161730C90924648 @default.
• W2022161730 hasIssue "2" @default.
• W2022161730 hasLocation W20221617301 @default.
• W2022161730 hasLocation W20221617302 @default.
• W2022161730 hasLocation W20221617303 @default.
• W2022161730 hasLocation W20221617304 @default.
• W2022161730 hasLocation W20221617305 @default.
• W2022161730 hasLocation W20221617306 @default.
• W2022161730 hasOpenAccess W2022161730 @default.
• W2022161730 hasPrimaryLocation W20221617301 @default.
• W2022161730 hasRelatedWork W1973107024 @default.
• W2022161730 hasRelatedWork W1998142511 @default.
• W2022161730 hasRelatedWork W2031089660 @default.
• W2022161730 hasRelatedWork W2044818650 @default.

• next